Gómez-Aleza et al. investigated the impact of RANK signaling loss on immune cell infiltration in PyMT mouse tumor cells and found that RANKL inhibition in luminal-like breast cancer with loss of RANK signaling improved the response to anti-CTLA-4 and anti-PD-L1 immunotherapy. Here, TNFSF11 is linked to neoplasm.